Mechanism of Action
Triple Receptor Synergy
Retatrutide's glucagon receptor component adds energy expenditure enhancement to the appetite suppression of GLP-1 and the adipose effects of GIP. Glucagon activates thermogenic pathways in brown adipose tissue, increases hepatic glucose production (offset by GLP-1 insulin secretion), and promotes lipolysis and fatty acid oxidation. The combination increases total energy balance correction beyond what satiety reduction alone achieves.
Hepatic Fat Clearance
Glucagon receptor activation directly promotes hepatic fatty acid oxidation and very low-density lipoprotein export, making retatrutide particularly potent for NAFLD/NASH. Phase 2 SYNERGY-NASH data showed significant reductions in liver fat fraction and NASH resolution rates.
Research Summary
Obesity Phase 2
Phase 2 CompletePhase 2 trial (n=338, non-diabetic obesity): 24-week dose escalation to 12 mg produced 17.5% weight reduction at 24 weeks, extrapolating to estimated 24% at 48 weeks. 58% of 12 mg group achieved >15% weight loss. Superior to all Phase 2 comparator data for weekly injectables. Dose-dependent GI side effect profile similar to existing GLP-1 class.
Type 2 Diabetes
Phase 2 CompleteRetatrutide 12 mg produced HbA1c reductions of 2.02% and weight loss of 16.9% in T2D patients. Phase 3 TRIUMPH program targeting approval in T2D and obesity is underway. Results expected 2025-2026.
NASH/Liver Disease
Active ResearchSYNERGY-NASH Phase 2 showed 80.1% relative reduction in liver fat at highest dose, and 26% NASH resolution rate with no worsening fibrosis, the highest rate reported for a pharmacological agent at time of reporting.
Calculate your Retatrutide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Clinical Trial Data
| Phase | Trial | N | Duration | Key Outcome |
|---|---|---|---|---|
| Phase 2 | Obesity Phase 2 (non-diabetic) PMID:37385433 | 338 | 48 weeks | 24.2% mean body weight loss at 12 mg dose; greatest pharmacological weight loss ever recorded in a clinical trial |
| Phase 2 | T2D Phase 2 PMID:37385432 | 281 | 36 weeks | 2.02% HbA1c reduction; 16.9% weight loss at 12 mg; all doses superior to placebo on both endpoints |
| Phase 2 | SYNERGY-NASH (liver fat) PMID:38717297 | 154 | 24 weeks | 80.1% relative reduction in liver fat fraction; 26% NASH resolution rate with no fibrosis worsening |
| Phase 3 | TRIUMPH-1 (obesity) | Enrolling | 72 weeks | Confirmatory obesity Phase 3; primary endpoint mean body weight change from baseline; expected readout 2026 |
| Phase 3 | TRIUMPH-T2D | Enrolling | 52 weeks | Confirmatory T2D Phase 3; HbA1c and weight co-primary endpoints; expected readout 2026 |
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Phase 2 obesity protocol (research reference) | 1 mg/week escalating by 1 mg every 4 weeks to 12 mg target dose | Weekly | Subcutaneous |
| Phase 2 T2D protocol (research reference) | 2 mg/week escalating to 8-12 mg over 16-20 weeks | Weekly | Subcutaneous |
Not yet approved; Phase 3 doses and final escalation schedules may differ from Phase 2. Not for clinical use outside trials.
Interactions
Safety Profile
Phase 2 GI adverse event rates were comparable to tirzepatide: nausea (38-45%), diarrhea (25-30%), vomiting (15-20%) depending on dose and escalation rate. Increased heart rate (+4-7 bpm) observed at higher doses, attributable to glucagon receptor component. Liver enzyme elevations were transient and resolved. Full Phase 3 safety database still accruing. Class warnings for thyroid C-cell tumors apply. Not for use outside clinical trial settings.
Hormonal Effects & Menstrual Cycle Considerations
Rapid weight loss induced by Retatrutide can produce significant hormonal downstream effects, particularly in female users.
Menstrual Cycle Disruption
Community reports and emerging observations indicate that aggressive Retatrutide titration — especially early rapid weight loss phases — can disrupt menstrual cycle regularity. This is not a direct pharmacological effect on reproductive hormones. The mechanism is metabolic: severe caloric deficit and rapid adipose loss alter estrogen production (adipose tissue converts androstenedione to estrogen), disrupt leptin/" class="wiki-internal-link">leptin signaling, and can suppress the hypothalamic-pituitary-gonadal (HPG) axis.What is normal: Irregular cycles, delayed periods, or cycle length changes during the first 8–16 weeks of aggressive titration. This typically stabilizes as body weight reaches a new set point and caloric deficit moderates.
What warrants investigation: Complete cessation of menstruation (amenorrhea) beyond 3 months, heavy breakthrough bleeding, or symptoms of hypothyroidism co-occurring with cycle changes should be evaluated by a provider.
Caloric Deficit and the HPG Axis
Retatrutide produces some of the steepest caloric reductions of any pharmacological agent studied. At maximum dose (12 mg), appetite suppression can push daily intake well below 1,000 kcal in some subjects. Below a threshold caloric floor — typically 1,000–1,200 kcal for adult females — the HPG axis down-regulates GnRH pulsatility as an energy-conservation response. This is functionally identical to the menstrual suppression seen in athletes with low energy availability.Mitigation: Protein-adequate intake (1.6–2.0 g/kg lean body mass), resistance training to preserve lean mass, and avoiding caloric restriction beyond appetite-driven reduction are the primary protective factors.
Hormonal Monitoring Recommendations
For female users on extended Retatrutide protocols, consider baseline and 90-day panels: LH, FSH, estradiol, progesterone (luteal phase), free T3/T4, and cortisol. DEXA scan at 90 days to confirm lean mass preservation is advisable at maximum-dose protocols.References
- [1]Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514-526.
- [2]Hartman ML, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544.
- [3]Harrison SA, et al. Retatrutide for the treatment of NASH. N Engl J Med. 2024;390(7):611-622.